Maalox suspension 250ml vials

$9.16

Maalox suspension 250ml vials

Quantity:

Description

Composition
Active substance:
100 ml of suspension contains: magnesium hydroxide (in gel form) – 4.0 g of aluminum hydroxide (in gel form) – 3.5 g, calculated as aluminum oxide, 2.3 g ;.
Excipients:
Hydrochloric acid 10% – 0.52815 g, citric acid monohydrate – 0.0655 g, peppermint leaf oil – 0.0126 g Mannitol – 0,250 g, domiphen bromide – 0.00422 g sodium saccharinate – 0.028 g Sorbitol 70 % – 1.429 g, 30% hydrogen peroxide – 0.065 g purified water to 100 ml.
Description:
The suspension is white homogeneous after shaking.
Product form:
Oral suspension. 250 ml of the suspension into a vial of polyethylene, polypropylene a sealed lid with tamper-evident seal and polyethylene. 1 bottle together with instructions for use placed in a cardboard box.
Contraindications
Severe renal insufficiency. Hypersensitivity to the active substances and other ingredients. Hypophosphatemia. Fructose intolerance (due to the presence of sorbitol in the composition of the drug). Children and adolescents under 15 years.
Carefully
Aluminum hydroxide may cause constipation, overdose magnesium salts can lead to the weakening of the intestinal peristalsis; in patients at high risk (patients with renal insufficiency, elderly patients), high doses of the drug can cause or exacerbate bowel obstruction and ileus. Aluminum hydroxide is poorly absorbed in the gastrointestinal tract, so in patients with normal renal function, systemic exposure is rare. 3 Prolonged treatment, use of excessive doses or the use of the normal dose of the drug due to weak admission phosphates with food can lead to phosphate deficiency (due to aluminum binding phosphate), which is accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia. Treatment of patients at risk of developing a phosphate deficiency or prolonged use of the drug should be carried out under medical supervision. In renal insufficiency, chronic administration may increase the plasma concentrations of magnesium and aluminum. In these patients, long-term use of the drug in high doses may develop encephalopathy, dementia, microcytic anemia or worsening of osteomalacia caused by dialysis. In patients with porphyria undergoing hemodialysis; Pregnancy and lactation (see. section “Pregnancy and lactation”) In Alzheimer’s disease.
Indications
Gastric ulcer and duodenal ulcer in the acute phase. Acute gastro, chronic gastroduodenitis with normal or elevated secretion in the acute phase. Hiatal hernia, reflyuksezofagite. Dyspepsia, or discomfort such as epigastric pain, heartburn, acid regurgitation after errors in the diet, excessive consumption of ethanol, coffee, nicotine and the like, dyspepsia, or discomfort such as epigastric pain, heartburn, acid regurgitation (and their prevention), resulting from use of certain drugs (non-steroidal anti-inflammatory drugs, steroids, etc..).
Interaction with other drugs
With quinidine: while the use of quinidine may increase serum concentrations of quinidine and development quinidine overdose
Since blockers of H2-histamine receptors, propranolol, atenolol, cefdinir, cefpodoxime, metoprolol, chloroquine, prostacyclin diflunisalom, digoxin, bisphosphonates, ethambutol, isoniazid, fluoroquinolones, sodium fluoride, glucocorticosteroids (described for prednisolone and dexamethasone), indomethacin, ketoconazole, lincosamides , phenothiazine antipsychotics, penicillamine, rosuvastatin, iron salts, levothyroxine: while receiving with the drug absorption is reduced Maaloks® above n eparatov in the gastrointestinal tract. In the case of a 2-hour interval between administration of these drugs and drug Maaloks® and 4-hour interval between the reception and Maaloks® fluoroquinolone drug in the majority of cases this undesirable interaction may be avoided.
With polystyrenesulfonate (kayeksalatom) when used together with the drug Maaloks® polystyrenesulfonate (kayeksalatom) should be careful because of the possible risk of reducing the effectiveness of the binding resin and potassium of metabolic alkalosis in patients with renal failure (for magnesium hydroxide and aluminum hydroxide), and intestinal obstruction (aluminum hydroxide).
Citrate: the combination of aluminum hydroxide with citrate may increase the plasma concentrations of aluminum, especially in patients with renal insufficiency.
Overdose
Symptoms of acute overdose combination of aluminum hydroxide and magnesium salts include diarrhea, abdominal pain and vomiting. In patients at risk of high doses of the drug can cause or exacerbate bowel obstruction or ileus (see. Section ”
Carefully “).
Treatment: aluminum and magnesium excreted in the urine. Treatment of acute overdose carried out using a replenishment liquid losses and forced diuresis. 4 patients with renal failure is necessary hemodialysis or peritoneal dialysis.
pharmachologic effect
Pharmacological group:
Antacid.
Pharmacodynamics:
Preparation neutralize free hydrochloric acid, without causing secondary hypersecretion of hydrochloric acid. In connection with an increase in pH when it is receiving reduced peptic activity of gastric juice. It has also absorbent and protective action, which decreases due to influence of disturbing factors on the mucosa.
Pharmacokinetics:
Hydroxides of aluminum and magnesium antacids topical considered practically not absorbed when taken in recommended doses and, accordingly, has no systemic effects.
Pregnancy and breast-feeding
The animals received a clear indication of the presence of teratogenic effect in aluminum hydroxide and magnesium hydroxide. At the moment, did not reveal any specific teratogenic effects when using the drug Maaloks® during pregnancy, however, due to the lack of clinical experience, its use during pregnancy is possible only if the potential benefits of its application to the mother justifies the potential risk to the fetus. appointment of the drug should be avoided during pregnancy in high doses and for a long time. When used according to the recommendations of the mother suction magnesium hydroxide and aluminum salts of combinations is limited, so the drug Maaloks® found compatible with breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
In compliance with the recommended dosing regimen side effects are negligible.
To indicate the incidence of undesirable side effects, use the following classification of the World Health Organization: – infrequent> 0.1% and
Disorders of immune system: unknown frequency: hypersensitivity reactions such as itching, urticaria, angioedema, and anaphylaxis.
Disorders of the gastrointestinal tract: Uncommon: diarrhea, constipation
Metabolic and Nutritional: unknown frequency: gipermagniemiya, giperalyuminemiya, hypophosphatemia (prolonged treatment or high doses, or dosage units upon receipt of the low content of phosphate in the food) which could lead to increased bone resorption, hypercalciuria, osteomalacia.
special instructions
Observe the 2-hour interval between the application of the drug and other drugs Maaloks® and 4-hour interval between drug intake Maaloks® and fluoroquinolones (see. See “The interaction with other drugs”). long destination Maaloks® formulation should be avoided in renal function. Aluminum hydroxide with low phosphate content in the diet may lead to failure of the phosphate in the body. Therefore, when using aluminum hydroxide, especially long-term, should ensure adequate intake of dietary phosphate.
Storage conditions
At a temperature of not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside. Prior to use, the vial should be shaken. Adults and adolescents over 15 years: 15 ml (1 tablespoon) 3-4 times a day through a 1 to 2 hours after meals and at bedtime. The dose should not exceed 6 tablespoons per day. When reflux esophagitis take medication after a short time after eating. The course of treatment should not exceed 2-3 months. If episodic application (e.g., discomfort after errors in the diet), take 15 ml dose.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

SANOFI AVENTIS GROUP

There are no reviews yet.

Add your review